AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Biomarker Guided Discharge of Heart Failure Patients

RecruitingNAAges 18 Years - anyAllOttawa Heart Institute Research Corporation
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria Exclusion Criteria: * Patient unable to provide blood samples or cannot participate in follow-up * Patient with end stage organ failure * Kidney: creatinine \>350 ฮผmol/L or Estimated GFR โ‰ค15 ml/min * Liver dysfunction: liver function test \>2.5 times normal * Lungs: pulmonary FEV1\<50% predicted * Patient requiring intubation * Patient with an admission NTproBNP measurement of \>30,000 pg/ml * Patient listed for heart transplant, or admitted specifically for transplant workup * Patient in cardiogenic shock * Patient with life expectancy of less than 6 months, or has major co-morbidities such as new stroke, cancer, pneumonia, or other serious life threatening illness * Patient with conditions that will make it difficult to discharge from hospital such as a fall or waiting for a long term care bed * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the trial, or may bias the result of the trial, or the patient's ability to participate in the trial * Patient who has participated in another research trial involving an investigational product in the past 30 days
๐Ÿ’Š

What it tests

  • Biomarker guided discharge algorithm
๐Ÿ“

Where

1 site
University of Ottawa Heart Institute
Ottawa, Canada
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy